VERAXA Biotech AG (NASDAQ: VRXA) has taken a significant step forward in the development of its lead BiTAC(R) T-cell engager (BiTAC-TCE) program by initiating cell line development. The company announced a partnership with ATUM, a U.S.-based contract research organization, to generate stable clonal cell lines using ATUM's proprietary Leap-In Transposase(R) technology. This collaboration is intended to support manufacturing, analytical development, and nonclinical studies required before the candidate can enter IND/CTA-enabling studies.
The BiTAC platform is designed to improve the selectivity of T-cell engagers, potentially reducing the toxicity associated with conventional approaches. This advancement is critical as VERAXA prepares its most advanced oncology candidate for future clinical development. The company recently expanded its research facilities in Heidelberg, Germany, increasing laboratory capacity as multiple oncology programs move toward clinical development.
According to VERAXA, the partnership with ATUM represents an important development milestone. ATUM's Leap-In Transposase technology is expected to facilitate the efficient generation of stable cell lines, which are essential for producing the therapeutic protein consistently and at scale. This step is crucial for advancing the program toward regulatory filings and eventual clinical trials.
The news underscores VERAXA's progress in the competitive field of cancer immunotherapy. By focusing on improving the selectivity of T-cell engagers, the company aims to address limitations of current therapies, particularly off-target toxicity. The BiTAC platform's unique design could offer a safer and more effective treatment option for patients with various cancers.
Investors and industry observers are watching VERAXA's developments closely. The company's stock is traded on the NASDAQ under the ticker VRXA, and further updates are expected as the program advances. For more information, visit the company's newsroom at https://ibn.fm/VRXA.
